Mortality Down for Rectal Cancer Surgery at NAPRC-Accredited Hospitals
By Elana Gotkine HealthDay Reporter
FRIDAY, April 19, 2024 -- National Accreditation Program for Rectal Cancer (NAPRC)-accredited hospitals have lower risk-adjusted mortality and morbidity for patients undergoing major rectal cancer surgery, according to a study published online March 28 in the Journal of the American College of Surgeons.
Calista M. Harbaugh, M.D., from the University of Michigan in Ann Arbor, and colleagues conducted a retrospective, observational study of Medicare beneficiaries aged 65 to 99 years with rectal cancer who underwent proctectomy from 2017 to 2020. The primary exposure was NAPRC accreditation; primary outcomes included mortality and 30-day complications, readmissions, and reoperations.
Sixty-five of the 1,985 hospitals (3.3 percent) were NAPRC-accredited. The researchers found that 10 percent of the 20,202 patients underwent proctectomy at an accredited hospital. The likelihood of having an elective procedure with a minimally invasive approach and sphincter preservation was higher for patients at accredited hospitals. Compared with nonaccredited hospitals, accredited hospitals had significantly lower risk-adjusted in-hospital mortality (1.1 versus 1.3 percent), 30-day mortality (2.1 versus 2.9 percent), 30-day complications (18.3 versus 19.4 percent), and one-year mortality rates (11.0 versus 12.1 percent).
"These results suggest that NAPRC hospitals provide safer surgical care, despite the fact that NAPRC standards do not directly address surgical safety," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.